TRIPHASIL-21 Drug Patent Profile
✉ Email this page to a colleague
When do Triphasil-21 patents expire, and when can generic versions of Triphasil-21 launch?
Triphasil-21 is a drug marketed by Wyeth Pharms and is included in one NDA.
The generic ingredient in TRIPHASIL-21 is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
Summary for TRIPHASIL-21
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Clinical Trials: | 2 |
| Patent Applications: | 339 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | TRIPHASIL-21 at DailyMed |
Recent Clinical Trials for TRIPHASIL-21
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Desmond Tutu HIV Centre | N/A |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for TRIPHASIL-21
US Patents and Regulatory Information for TRIPHASIL-21
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Pharms | TRIPHASIL-21 | ethinyl estradiol; levonorgestrel | TABLET;ORAL-21 | 019192-001 | Nov 1, 1984 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TRIPHASIL-21
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Wyeth Pharms | TRIPHASIL-21 | ethinyl estradiol; levonorgestrel | TABLET;ORAL-21 | 019192-001 | Nov 1, 1984 | ⤷ Try a Trial | ⤷ Try a Trial |
| Wyeth Pharms | TRIPHASIL-21 | ethinyl estradiol; levonorgestrel | TABLET;ORAL-21 | 019192-001 | Nov 1, 1984 | ⤷ Try a Trial | ⤷ Try a Trial |
| Wyeth Pharms | TRIPHASIL-21 | ethinyl estradiol; levonorgestrel | TABLET;ORAL-21 | 019192-001 | Nov 1, 1984 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TRIPHASIL-21
See the table below for patents covering TRIPHASIL-21 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 264728 | ⤷ Try a Trial | |
| Germany | 1468643 | Verfahren zur Herstellung von 2-(1'-Tetralyliden-aethyl)-2-alkyl-cyclopentan-1,3-dionen | ⤷ Try a Trial |
| France | 1276081 | Nouveaux intermédiaires cétoniques en vue de la synthèse des stéroïdes et leur procédé de préparation | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TRIPHASIL-21
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1214076 | SZ 49/2008 | Austria | ⤷ Try a Trial | PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON |
| 0771217 | 07C0001 | France | ⤷ Try a Trial | PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804 |
| 1453521 | 93156 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
